Kineret launches in the UK following clinician consultation

After its European Medicines Agency (EMA) approval in this indication in April, Swedish Orphan Biovitrum's (STO: SOBI) Kineret (anakinra) has launched in the UK for the treatment of adult onset Still's disease (AOSD) and systemic-onset juvenile idiopathic arthritis (SOJIA).

Kineret, a protein which first entered use in the USA in 2001, was already available in the UK for rheumatoid arthritis and cryopyrin-associated period syndromes. This label extension is based on analyses of around 400 patients with AOSD and early onset Still's disease, which are genetically similar to SOJIA.

Commenting on the launch of Kineret, clinical immunology and allergy consultant at St James Hospital Leeds, Sisina Sabvic, said: "This is an important step in providing additional therapeutic options for the UK Still’s patients, especially for those who have not responded to previous treatments.